To look at the effectiveness of sacituzumab tirumotecan (MK-2870) in treating participants with treatment-refractory unresectable and/or metastatic anal/rectal…

Phase 2Sacituzumab TirumotecanRefractory Metastatic+2 more

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07511023

Phase 2

Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma

To learn if sacituzumab tirumotecan can help to control advanced or metastatic SMARCB1-deficient RMC in patients whose disease has progressed after receiving a…

Phase IISacituzumabTirumotecan+1 more

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07438626